News und Analysen

Image source: The Motley Fool.

Exelixis (NASDAQ: EXEL)Q2 2024 Earnings CallAug 06, 2024, 5:00 p.m. ET

Operator

Continue reading

Source Fool.com

Many billionaire investors are going all in on artificial intelligence (AI). That's understandable. AI is quickly being integrated into businesses' day-to-day operations. The leaders in the field

Image source: The Motley Fool.

Exelixis (NASDAQ: EXEL)Q1 2024 Earnings CallApr 30, 2024, 5:00 p.m. ET

Operator

Continue reading

Source Fool.com

Shares of Novocure (NASDAQ: NVCR) jumped 18.3% this week, according to data from S&P Global Market Intelligence, after the company announced encouraging results from a phase 3 study of its Tumor

Shares of Novocure (NASDAQ: NVCR) were jumping 6.3% higher as of 11:15 a.m. ET on Thursday after rising as much as 9.2% earlier in the day. The nice gain came after the company announced results

What is a reasonable sum of money to start investing in stocks? $10,000? $1,000? $500? The truth is, thanks to online brokers who now offer trades at low or no fees and fractional shares, investors

Danish pharmaceutical company Novo Nordisk (NYSE: NVO) just made the headlines for something other than Ozempic. Well, sort of. One of the company's subsidiaries, Novo Holdings, is responsible for

Image source: The Motley Fool.

Exelixis (NASDAQ: EXEL)Q4 2023 Earnings CallFeb 06, 2024, 5:00 p.m. ET

Operator

Continue reading

Source Fool.com

Shares of Catalent (NYSE: CTLT) rose by 9.7% on Monday after the pharmaceutical contract manufacturing and drug delivery technology specialist agreed to be acquired by Novo Holdings, the parent

A major acquisition by its controlling shareholder pushed Novo Nordisk's (NYSE: NVO) U.S.-listed shares 4% higher on Monday. As a result of the deal, Novo Nordisk will acquire from that shareholder

Invitae (NYSE: NVTA) has grown revenue over time, but the genetic testing specialist has failed to turn that into profit. Instead, the company burned through more and more cash, prompting it to

Image source: The Motley Fool.

Invitae (NYSE: NVTA)Q3 2023 Earnings CallNov 08, 2023, 4:30 p.m. ET

Operator

Continue reading

Source Fool.com

It wasn't a wise move for investors to hold or buy Sage Therapeutics (NASDAQ: SAGE) shares on Tuesday. Its price tumbled by nearly 5% as the market digested the healthcare company's third-quarter

Genetic-testing company, Invitae (NYSE: NVTA), isn't as easy to understand as it might seem. After more than a year of pivoting and scaling down its operations, changing its leadership, and

Cancer is one of the leading causes of death worldwide. That's why dozens of healthcare companies are constantly seeking new ways to treat, diagnose, or prevent it.

Medical device specialist

Image source: The Motley Fool.

Exelixis (NASDAQ: EXEL)Q3 2023 Earnings CallNov 01, 2023, 5:00 p.m. ET

Operator

Continue reading

Source Fool.com

Invitae (NYSE: NVTA) recently announced news that made its shares pop. The genetic testing company won a regulatory nod for a first-of-its-kind test for hereditary cancer risk. The U.S. Food and

Shares of Blueprint Medicines (NASDAQ: BPMC) closed up 25.6% on Thursday after the cancer and blood discorder therapy company announced stronger-than-expected quarterly results.

Blueprint Medicines'

Oncology-focused healthcare company Novocure (NASDAQ: NVCR) wasn't much of a cure for anyone's ill finances on Thursday. Its share price dived by nearly 8% on the day after management released its